Circulating Tumor DNA Correlates with Disease Burden in Patients with Metastatic RET -Mutated Sporadic Medullary Thyroid Cancer

Abstract

Get full access to this article

View all access options for this article.

References

1. Gild

, Clifton-Bligh

, Wirth

, et al. Medullary thyroid cancer: Updates and challenges. Endocr Rev 2023;44(5):934-946; doi: 10.1210/endrev/bnad013.

2. Altinay

, Kara

, Gülbağcı

, et al. Molecular profiling of sporadic medullary thyroid carcinomas—a next-generation sequencing-based study. Pol J Pathol 2025;76(3):195-213; doi: 10.5114/pjp.2025.156557.

3. Vuong

, Odate

, Ngo

HTT

, et al. Clinical significance of RET and RAS mutations in sporadic medullary thyroid carcinoma: A meta-analysis. Endocr Relat Cancer 2018;25(6):633-641; doi: 10.1530/ERC-18-0056.

4. Prete

, Torregrossa

, Gambale

, et al. The usefulness of the international grading system in the management of sporadic medullary thyroid carcinoma. Thyroid 2025;35(4):387-396; doi: 10.1089/thy.2024.0444.

5. Cote

, Evers

, Hu

, et al. Prognostic significance of circulating RET M918T mutated tumor DNA in patients with advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 2017;102(9):3591-3599; doi: 10.1210/jc.2017-01039.

6. Allin

, Shaikh

, Carter

, et al. Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer. Eur J Cancer 2018;103:165-175; doi: 10.1016/j.ejca.2018.08.013.

7. Ciampi

, Casalini

, Ramone

, et al. Liquid biopsy-based RET mutation profiling to guide RET inhibitor treatment in sporadic medullary thyroid carcinoma may be useful in cases with high tumor burden and progressive disease. Thyroid. 2026;36(2):188-194; doi: 10.1177/10507256261416836.

8. Carr

, Welch

. Assessing the clinical utility of liquid biopsies across 5 potential indications from therapy selection to population screening: A review. JAMA Intern Med 2023;183(10):1144-1151; doi: 10.1001/jamainternmed.2023.3603.